NKG2D ligands in tumor immunity

NKG2D Ligands in Tumor Immunity: Two Sides of a Coin

The activating/co-stimulatory receptor NKG2D (natural-killer group 2, member D) is expressed on the surface of all human NK, NKT, CD8(+) T, and subsets of γδ(+) T cells. The significance of NKG2D function in tumor immunity has been well demonstrated in experimental animal models. However, the role of human NKG2D ligands in regulating tumor immunity and cancer prognosis had been controversial in...

ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15.

ULBPs are human ligands for NKG2D, an activating receptor expressed on natural killer (NK) cells, NK1.1(+) T cells, and T cells. ULBPs are expressed by a variety of leukemias, carcinomas, melanomas, and tumor cell lines. ULBP expression correlates with improved survival in cancer patients, however, the nature of the immune response that ULBPs elicit is not well understood. We report that ectopi...

NKG2D ligands link oncogenic RAS to innate immunity

RAS is constitutively active in multiple types of tumor cells. We have recently demonstrated that H-RASV12 enhances the translation of ligands for the activating immune receptor NKG2D, hence rendering cells more susceptible to natural killer (NK) cell-mediated lysis. This effect depends on MAPK and PI3K signaling, but not on the DNA damage response.

Chimeric NKG2D-Modified T Cells NKG2D Ligands and Can Be Targeted by Mouse Tumor Vasculature Expresses

Review of NKG2D function and its related ligands: review article

The natural killer group 2D (NKG2D) is a transmembrane protein and a member of the CD94/NKG2 family of C-type lectin-like receptors. NKG2D is encoded by the KLRK1 gene, which is located in the NK-gene complex (NKC) placed on chromosomes 6 and 12 in mice and humans, respectively. NKG2D forms a homodimer structure and binds through ectodomains with its related ligands. Each of its monomers consis...